What is the Origin of SLCO1B1?

The term is an acronym for Solute Carrier Organic Anion Transporter Family Member 1B1, a systematic nomenclature based on the protein's function as a membrane transport protein. Its clinical relevance was solidified through pharmacogenomic studies demonstrating a clear link between specific gene variants and an individual's ability to clear certain drugs from the circulation. This gene is a key player in personalized medicine and drug safety.

What is the Mechanism of SLCO1B1?

The OATP1B1 protein acts as an influx transporter, actively moving its substrates from the bloodstream into the hepatocyte, the main liver cell, where they can be metabolized and excreted. A common polymorphism, the SLCO1B1 c.521T>C variant, results in a reduced-function transporter, leading to higher systemic drug exposure for statins like simvastatin. This reduced clearance increases the concentration of the drug in muscle tissue, consequently raising the risk of statin-induced myopathy.

SLCO1B1

Meaning

SLCO1B1 is a gene that provides instructions for making a protein called Organic Anion Transporting Polypeptide 1B1 (OATP1B1), a crucial transporter protein expressed on the membrane of liver cells. This transporter is responsible for the hepatic uptake of a wide range of endogenous compounds, including bilirubin and bile acids, as well as many clinically relevant medications, notably statins. Genetic polymorphisms in SLCO1B1 significantly influence drug pharmacokinetics and the risk of adverse drug reactions.